Browsing Tag
Inc.
380 posts
Heartflow’s AI-based plaque analysis validated at AHA 2025 as strongest predictor of coronary artery disease risk
Discover how Heartflow’s AHA 2025 results validate AI-based plaque-volume analysis as a new benchmark in coronary risk prediction—read more.
Merck’s enlicitide slashes LDL-C by 55.8%: Could this daily pill replace PCSK9 injections?
Merck’s enlicitide cuts LDL-C by over 55% in Phase 3 trial. Could it become the first oral PCSK9 inhibitor to transform ASCVD treatment?
Castellum, Inc. delivers first-ever positive net income in Q3 2025 amid accelerating defense-tech contracts
Find out how Castellum, Inc. achieved its first-ever positive net income in Q3 2025 and what it signals for its defense-tech transformation.
Tesla and XPeng see surging insurance premiums as SunCar expands its AI technology development center
Find out how SunCar’s AI technology center is driving explosive insurance-premium growth for Tesla and XPeng while reshaping the EV service ecosystem.
Hyperscale Data fortifies balance sheet with $125m raise, doubling down on bitcoin-backed AI expansion
Find out how Hyperscale Data’s $125 million raise is powering its bold bitcoin-backed AI infrastructure expansion.
Can ECARX challenge legacy Tier-1s in the intelligent cockpit race? A look at global platform shifts
ECARX pushes into the intelligent cockpit market, challenging traditional Tier‑1 automotive suppliers with full‑stack digital cabin solutions. Read how.
Is Merck building the next great cardiometabolic franchise? A closer look at WINREVAIR, enlicitide and Ohtuvayre
See how Merck is building a cardiometabolic growth engine with WINREVAIR, enlicitide and Ohtuvayre—and what it means for investors.
Netflix just split its stock 10-for-1—here’s what it means for shareholders and employees
Find out how Netflix’s 10-for-1 stock split is reshaping investor access, employee ownership, and shareholder sentiment today!
Can Merck sustain its oncology-led momentum? Keytruda, WINREVAIR, and pipeline drive Q3 beat
Merck’s Q3 2025 results beat expectations on Keytruda strength and a rising pipeline. Explore what’s driving EPS upgrades and future growth bets.
BWXT expands into modular nuclear manufacturing with Rolls-Royce SMR steam generator contract
BWXT signs steam generator contract with Rolls‑Royce SMR to scale modular nuclear components globally. Find out what this means for nuclear manufacturing now.